A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Glucagon-Like Peptide 1; rGLP-1 protein; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Renally impaired with a historical diagnosis of type 2 diabetes mellitus and is experiencing inadequate glycemic control on their current regime of diet and exercise or their antidiabetic therapy of metformin, TZD, SU, or any combination of these oral antidiabetic medications

• BMI >/=20 kg/m2 and
• Fasting C-peptide >/=0.8 ng/mL (>/=0.26 nmol/L)

• HbA1c between 7.0% and 10.0%, inclusive.

Exclusion Criteria:

• History of cancer

• History of treated diabetic gastroparesis

• Current biliary disease or history of pancreatitis

• History of significant gastrointestinal surgery

• Recent clinically significant cardiovascular and/or cerebrovascular disease

• History of human immunodeficiency virus infection

• Abnormal liver function or acute symptomatic infection with hepatitis B or hepatitis C

• Female subject is pregnant (confirmed by laboratory testing), lactating, or <6 weeks postpartum

• Known allergy to any GLP 1 analogue, sitagliptin, other study medications' excipients, excipients of albiglutide, or Baker's yeast

• Receipt of any investigational drug or sitagliptin within the 30 days or 5 half lives, whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies